BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 22261191)

  • 1. Varicella-zoster virus-specific cell-mediated immunity in subjects with herpes zoster.
    Otani N; Yamanishi K; Sakaguchi Y; Imai Y; Shima M; Okuno T
    J Immunol Methods; 2012 Mar; 377(1-2):53-5. PubMed ID: 22261191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay.
    Sadaoka K; Okamoto S; Gomi Y; Tanimoto T; Ishikawa T; Yoshikawa T; Asano Y; Yamanishi K; Mori Y
    J Infect Dis; 2008 Nov; 198(9):1327-33. PubMed ID: 18774884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of varicella zoster virus-specific cell-mediated immunity by using an interferon-γ enzyme-linked immunosorbent assay.
    Hayashida K; Ozaki T; Nishimura N; Gotoh K; Funahashi K; Nakane K; Gomi Y; Manabe S; Ishikawa T; Yamanishi K
    J Immunol Methods; 2015 Nov; 426():50-5. PubMed ID: 26232696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine.
    Levin MJ; Smith JG; Kaufhold RM; Barber D; Hayward AR; Chan CY; Chan IS; Li DJ; Wang W; Keller PM; Shaw A; Silber JL; Schlienger K; Chalikonda I; Vessey SJ; Caulfield MJ
    J Infect Dis; 2003 Nov; 188(9):1336-44. PubMed ID: 14593591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular and Humoral Responses to a Second Dose of Herpes Zoster Vaccine Administered 10 Years After the First Dose Among Older Adults.
    Levin MJ; Schmader KE; Pang L; Williams-Diaz A; Zerbe G; Canniff J; Johnson MJ; Caldas Y; Cho A; Lang N; Su SC; Parrino J; Popmihajlov Z; Weinberg A
    J Infect Dis; 2016 Jan; 213(1):14-22. PubMed ID: 26452397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection.
    Schub D; Janssen E; Leyking S; Sester U; Assmann G; Hennes P; Smola S; Vogt T; Rohrer T; Sester M; Schmidt T
    J Infect Dis; 2015 Feb; 211(4):600-12. PubMed ID: 25180236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varicella-zoster virus-specific cell-mediated immune responses in HIV-infected adults.
    De Castro N; Carmagnat M; Kernéis S; Scieux C; Rabian C; Molina JM
    AIDS Res Hum Retroviruses; 2011 Oct; 27(10):1089-97. PubMed ID: 21417759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of varicella-zoster virus cell-mediated immune response after varicella booster vaccination.
    Berger R; Luescher D; Just M
    Postgrad Med J; 1985; 61 Suppl 4():143-5. PubMed ID: 3014472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Varicella-zoster virus-specific cell-mediated immunity by interferon-γ Enzyme-Linked Immunosorbent Assay in adults ≥50 years of age administered a herpes zoster vaccine.
    Yang P; Chen Z; Zhang J; Li W; Zhu C; Qiu P; Quan Y; Cui X; Yuan L; Jiang C
    J Med Virol; 2019 May; 91(5):829-835. PubMed ID: 30613990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An inverse correlation of VZV skin-test reaction, but not antibody, with severity of herpes zoster skin symptoms and zoster-associated pain.
    Asada H; Nagayama K; Okazaki A; Mori Y; Okuno Y; Takao Y; Miyazaki Y; Onishi F; Okeda M; Yano S; Kumihashi H; Gomi Y; Maeda K; Ishikawa T; Iso H; Yamanishi K;
    J Dermatol Sci; 2013 Mar; 69(3):243-9. PubMed ID: 23183011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varicella-Zoster virus-specific cell-mediated immunity in HIV-infected children receiving highly active antiretroviral therapy.
    Weinberg A; Wiznia AA; LaFleur BJ; Shah S; Levin MJ
    J Infect Dis; 2004 Jul; 190(2):267-70. PubMed ID: 15216460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine.
    Weinberg A; Zhang JH; Oxman MN; Johnson GR; Hayward AR; Caulfield MJ; Irwin MR; Clair J; Smith JG; Stanley H; Marchese RD; Harbecke R; Williams HM; Chan IS; Arbeit RD; Gershon AA; Schödel F; Morrison VA; Kauffman CA; Straus SE; Schmader KE; Davis LE; Levin MJ;
    J Infect Dis; 2009 Oct; 200(7):1068-77. PubMed ID: 19712037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic varicella zoster virus reactive effector memory T-cells impaired in the elderly and in kidney transplant recipients.
    van Besouw NM; Verjans GM; Zuijderwijk JM; Litjens NH; Osterhaus AD; Weimar W
    J Med Virol; 2012 Dec; 84(12):2018-25. PubMed ID: 23080511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A community-based survey of varicella-zoster virus-specific immune responses in the elderly.
    Tang H; Moriishi E; Okamoto S; Okuno Y; Iso H; Asada H; Yamanishi K; Mori Y;
    J Clin Virol; 2012 Sep; 55(1):46-50. PubMed ID: 22771002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-gamma release assay: a simple method for detection of varicella-zoster virus-specific cell-mediated immunity.
    Otani N; Baba K; Okuno T
    J Immunol Methods; 2009 Dec; 351(1-2):71-4. PubMed ID: 19818791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.
    Distler E; Schnürer E; Wagner E; von Auer C; Plachter B; Wehler D; Huber C; Kolbe K; Meyer RG; Herr W
    Biol Blood Marrow Transplant; 2008 Dec; 14(12):1417-24. PubMed ID: 19041065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of varicella-zoster virus-specific immunity of patients with diabetes mellitus and healthy individuals.
    Okamoto S; Hata A; Sadaoka K; Yamanishi K; Mori Y
    J Infect Dis; 2009 Nov; 200(10):1606-10. PubMed ID: 19821719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased incidence of herpes zoster in patients on renal replacement therapy cannot be explained by intrinsic defects of cellular or humoral immunity to varicella-zoster virus.
    Rondaan C; de Joode AAE; van Assen S; Bos NA; Westerhuis R; Westra J
    Antiviral Res; 2018 Oct; 158():206-212. PubMed ID: 30102958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between cell-mediated immunity to Varicella-Zoster virus and aging in subjects from the community-based Shozu Herpes Zoster study.
    Shirane R; Tang H; Hayashi K; Okuno Y; Iso H; Asada H; Yamanishi K; Mori Y;
    J Med Virol; 2017 Feb; 89(2):313-317. PubMed ID: 27420414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.
    Sullivan NL; Reuter-Monslow MA; Sei J; Durr E; Davis CW; Chang C; McCausland M; Wieland A; Krah D; Rouphael N; Mehta AK; Mulligan MJ; Pulendran B; Ahmed R; Vora KA
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29743372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.